Drug persistence with rivaroxaban therapy in atrial fibrillation patients--results from the Dresden non-interventional oral anticoagulation registry

Abstract

Our data indicate that overall persistence with rivaroxaban therapy is high, with a discontinuation rate of ∼15% in the first year of treatment and few additional discontinuations thereafter.